Index RUT
P/E -
EPS (ttm) -0.13
Insider Own 3.82%
Shs Outstand 226.06M
Perf Week 6.17%
Market Cap 1.52B
Forward P/E 13.08
EPS next Y 0.50
Insider Trans -14.49%
Shs Float 222.93M
Perf Month 3.97%
Income -28.24M
PEG -
EPS next Q 0.06
Inst Own 73.32%
Short Float 3.27%
Perf Quarter 24.10%
Sales 258.21M
P/S 5.87
EPS this Y 326.92%
Inst Trans 7.29%
Short Ratio 2.87
Perf Half Y 106.96%
Book/sh 0.60
P/B 10.93
EPS next Y 69.49%
ROA -8.33%
Short Interest 7.29M
Perf Year 82.68%
Cash/sh 0.22
P/C 29.52
EPS next 5Y -
ROE -19.67%
52W Range 3.06 - 6.76
Perf YTD 44.69%
Dividend Est. -
P/FCF 376.12
EPS past 5Y 38.68%
ROI -10.25%
52W High -3.25%
Beta 0.44
Dividend TTM -
Quick Ratio 1.69
Sales past 5Y 73.26%
Gross Margin 34.16%
52W Low 113.73%
ATR (14) 0.25
Dividend Ex-Date -
Current Ratio 5.16
EPS Y/Y TTM 62.29%
Oper. Margin 8.38%
RSI (14) 60.66
Volatility 4.33% 3.72%
Employees 624
Debt/Eq 1.05
Sales Y/Y TTM 67.59%
Profit Margin -10.94%
Recom 1.00
Target Price 8.38
Option/Short Yes / Yes
LT Debt/Eq 1.04
EPS Q/Q -29.52%
Payout -
Rel Volume 1.08
Prev Close 6.20
Sales Surprise 2.47%
EPS Surprise -420.00%
Sales Q/Q 47.86%
Earnings Feb 28 AMC
Avg Volume 2.54M
Price 6.54
SMA20 4.07%
SMA50 9.98%
SMA200 45.71%
Trades
Volume 2,752,008
Change 5.48%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-19-23 Resumed
Raymond James
Strong Buy
$5
Oct-13-22 Initiated
Mizuho
Buy
$5
Nov-11-21 Upgrade
Raymond James
Outperform → Strong Buy
$5
Nov-09-21 Initiated
Cantor Fitzgerald
Overweight
$4.50
Jun-04-19 Initiated
Jefferies
Buy
$8
Apr-15-19 Reiterated
H.C. Wainwright
Buy
$10 → $13
Feb-07-19 Resumed
H.C. Wainwright
Buy
$10
Dec-11-17 Reiterated
Maxim Group
Buy
$13 → $8
Nov-14-17 Upgrade
Raymond James
Mkt Perform → Outperform
Jan-23-17 Upgrade
Maxim Group
Hold → Buy
$13
Aug-01-16 Downgrade
Maxim Group
Buy → Hold
Jul-25-16 Reiterated
Maxim Group
Buy
$24 → $14
May-13-15 Reiterated
Maxim Group
Buy
$18 → $24
Dec-08-14 Initiated
Oppenheimer
Outperform
$20
Dec-01-14 Reiterated
Maxim Group
Buy
$16 → $18
Show Previous Ratings
Apr-19-24 05:45PM
Apr-17-24 05:50PM
Apr-10-24 05:45PM
Apr-09-24 11:07AM
Apr-05-24 08:50AM
05:50PM
Loading…
Apr-01-24 05:50PM
Mar-22-24 05:50PM
Mar-20-24 08:50AM
Mar-18-24 09:55AM
09:30AM
Mar-15-24 05:50PM
Mar-11-24 07:00AM
Mar-05-24 12:00PM
07:00AM
Mar-04-24 08:50AM
09:55AM
Loading…
Mar-01-24 09:55AM
09:30AM
Feb-29-24 11:06AM
10:37AM
(Thomson Reuters StreetEvents)
Feb-28-24 05:30PM
(Associated Press Finance)
04:42PM
04:10PM
04:05PM
Feb-22-24 05:45PM
Feb-21-24 05:50PM
04:05PM
07:00AM
Feb-15-24 05:45PM
08:50AM
Feb-07-24 05:45PM
09:30AM
Loading…
Feb-06-24 09:30AM
Feb-05-24 09:55AM
Feb-02-24 05:50PM
Jan-30-24 08:50AM
Jan-19-24 09:55AM
Jan-17-24 09:30AM
Jan-10-24 08:50AM
Jan-08-24 07:00AM
Jan-05-24 12:00PM
Dec-26-23 09:30AM
Dec-25-23 09:55AM
Dec-18-23 04:05PM
Dec-12-23 07:00AM
Dec-08-23 09:30AM
Dec-06-23 09:40AM
Nov-22-23 09:30AM
Nov-17-23 06:29PM
Nov-16-23 07:00AM
Nov-10-23 11:05AM
Nov-09-23 04:25PM
10:04AM
(Thomson Reuters StreetEvents)
Nov-08-23 04:49PM
(Associated Press Finance)
04:05PM
Nov-06-23 09:30AM
Nov-02-23 05:45PM
Nov-01-23 07:00AM
Oct-27-23 05:45PM
Oct-25-23 05:50PM
Oct-17-23 05:50PM
Oct-09-23 05:50PM
Sep-29-23 09:30AM
Sep-27-23 05:50PM
Sep-21-23 05:50PM
Sep-14-23 05:50PM
Sep-13-23 09:30AM
Aug-10-23 02:31PM
11:50AM
09:40AM
06:46AM
(Thomson Reuters StreetEvents)
Aug-09-23 06:40PM
05:37PM
04:05PM
Aug-02-23 07:00AM
Jul-28-23 08:59AM
Jul-26-23 11:30AM
Jul-25-23 05:12PM
Jul-20-23 05:50PM
Jul-19-23 07:00AM
Jul-13-23 05:50PM
Jul-07-23 07:32AM
Jun-23-23 10:31AM
Jun-22-23 09:18AM
Jun-21-23 03:21PM
10:46AM
Jun-19-23 10:28AM
Jun-16-23 10:43AM
10:26AM
Jun-14-23 12:17PM
11:48AM
09:40AM
Jun-13-23 09:18AM
Jun-08-23 11:49AM
11:20AM
Jun-07-23 12:31PM
Jun-06-23 11:14AM
Jun-05-23 12:43PM
10:22AM
Jun-02-23 10:59AM
Jun-01-23 11:59AM
May-31-23 10:46AM
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ELMS STEVE Director Mar 19 '24 Sale 6.08 411,829 2,503,920 2,115,671 Mar 19 09:48 PM ELMS STEVE Director Mar 18 '24 Sale 6.01 49,887 299,821 2,527,500 Mar 19 09:48 PM ELMS STEVE Director Mar 15 '24 Sale 6.01 183,008 1,099,878 2,577,387 Mar 15 09:00 PM ELMS STEVE Director Mar 14 '24 Sale 6.05 448,276 2,712,070 2,760,395 Mar 15 09:00 PM ELMS STEVE Director Mar 13 '24 Sale 6.21 407,000 2,527,470 3,208,671 Mar 15 09:00 PM Grossman Jerrold B Director Aug 30 '23 Buy 3.71 130,000 482,144 443,265 Aug 30 04:58 PM KWON YOUNG Director Aug 24 '23 Buy 3.90 25,000 97,500 277,401 Aug 24 07:53 PM Fong Bryant Director Aug 22 '23 Sale 3.87 1,433,304 5,544,737 0 Aug 23 08:30 PM Grossman Adam S President and CEO Aug 18 '23 Sale 4.15 250,000 1,038,350 2,273,085 Aug 18 09:46 PM LENZ BRIAN EVP, CFO Aug 16 '23 Sale 4.45 178,184 793,400 782,013 Aug 17 09:30 PM Grossman Adam S President and CEO Aug 16 '23 Sale 4.38 3 13 2,523,085 Aug 17 09:30 PM Grossman Adam S President and CEO Aug 15 '23 Option Exercise 3.11 2,100,459 6,536,448 4,623,544 Aug 17 09:30 PM LENZ BRIAN EVP, CFO Aug 15 '23 Option Exercise 3.11 809,262 2,514,363 1,591,275 Aug 17 09:30 PM Grossman Adam S President and CEO Aug 15 '23 Sale 4.54 510,469 2,318,959 4,113,075 Aug 17 09:30 PM LENZ BRIAN EVP, CFO Aug 15 '23 Sale 4.60 211,578 972,730 782,013 Aug 17 09:30 PM
Index -
P/E -
EPS (ttm) -0.93
Insider Own 11.04%
Shs Outstand 88.93M
Perf Week 0.57%
Market Cap 82.55M
Forward P/E -
EPS next Y -0.96
Insider Trans 0.14%
Shs Float 79.36M
Perf Month -7.45%
Income -82.09M
PEG -
EPS next Q -0.22
Inst Own 46.03%
Short Float 1.56%
Perf Quarter -0.51%
Sales 0.32M
P/S 257.96
EPS this Y 8.76%
Inst Trans -1.71%
Short Ratio 2.89
Perf Half Y -2.61%
Book/sh 2.17
P/B 0.43
EPS next Y -12.63%
ROA -33.36%
Short Interest 1.24M
Perf Year -23.53%
Cash/sh 2.05
P/C 0.45
EPS next 5Y -
ROE -36.50%
52W Range 0.88 - 1.57
Perf YTD -3.86%
Dividend Est. -
P/FCF -
EPS past 5Y 8.31%
ROI -42.24%
52W High -41.06%
Beta 1.13
Dividend TTM -
Quick Ratio 10.25
Sales past 5Y 292.67%
Gross Margin 98.98%
52W Low 5.15%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 10.25
EPS Y/Y TTM -147.20%
Oper. Margin -28723.77%
RSI (14) 40.38
Volatility 5.41% 5.60%
Employees 72
Debt/Eq 0.01
Sales Y/Y TTM -99.04%
Profit Margin -25337.96%
Recom 1.29
Target Price 7.00
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 14.16%
Payout -
Rel Volume 0.42
Prev Close 0.91
Sales Surprise -95.12%
EPS Surprise 15.15%
Sales Q/Q -99.51%
Earnings Feb 29 BMO
Avg Volume 428.70K
Price 0.93
SMA20 -5.69%
SMA50 -13.76%
SMA200 -9.76%
Trades
Volume 182,039
Change 1.25%
Date
Action
Analyst
Rating Change
Price Target Change
May-23-23 Initiated
Robert W. Baird
Outperform
$7
Sep-07-22 Initiated
CapitalOne
Overweight
$7
Apr-29-21 Initiated
Maxim Group
Buy
$20
Apr-23-21 Resumed
Cowen
Outperform
$10 → $18
Mar-31-21 Initiated
Wedbush
Outperform
$21
Mar-31-21 Initiated
Jefferies
Buy
$21
Feb-14-18 Downgrade
JP Morgan
Neutral → Underweight
Feb-02-18 Initiated
H.C. Wainwright
Buy
$10
Aug-09-16 Reiterated
FBR Capital
Mkt Perform
$9 → $8
Feb-23-16 Reiterated
FBR Capital
Mkt Perform
$14 → $10
Feb-23-16 Downgrade
Morgan Stanley
Equal-Weight → Underweight
Feb-23-16 Downgrade
Barclays
Overweight → Equal Weight
$12 → $6
Feb-22-16 Downgrade
Citigroup
Buy → Neutral
Dec-29-15 Downgrade
JP Morgan
Overweight → Neutral
$65 → $15
Dec-28-15 Reiterated
Piper Jaffray
Overweight
$63 → $10
Dec-28-15 Downgrade
FBR Capital
Outperform → Mkt Perform
$73 → $14
Dec-17-15 Initiated
UBS
Buy
$55
Oct-05-15 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Sep-03-15 Initiated
Citigroup
Buy
Aug-18-15 Initiated
FBR Capital
Outperform
$73
Show Previous Ratings
Apr-16-24 04:05PM
Mar-21-24 07:00AM
Mar-01-24 09:06AM
Feb-29-24 11:25PM
(Thomson Reuters StreetEvents) -7.26%
08:11AM
07:27AM
Loading…
07:27AM
(Associated Press Finance)
07:00AM
Feb-27-24 07:00AM
Feb-22-24 07:00AM
Dec-29-23 07:00AM
Dec-04-23 07:00AM
Nov-24-23 07:00AM
Nov-16-23 07:00AM
Nov-03-23 09:12AM
01:34AM
(Thomson Reuters StreetEvents)
10:08AM
Loading…
Nov-02-23 10:08AM
07:10AM
(Associated Press Finance)
07:00AM
Oct-26-23 07:00AM
Oct-23-23 10:08AM
Sep-05-23 07:00AM
Aug-16-23 10:05AM
Aug-11-23 06:15AM
Aug-03-23 08:25AM
07:19AM
(Associated Press Finance)
07:00AM
Jul-31-23 07:54AM
Jul-30-23 02:17PM
Jul-28-23 04:19PM
Jul-27-23 10:53AM
07:00AM
Loading…
07:00AM
06:00AM
Jul-11-23 08:53PM
Jun-28-23 02:58PM
(American City Business Journals)
Jun-27-23 04:05PM
Jun-01-23 08:04PM
May-31-23 04:01PM
May-25-23 07:00AM
May-05-23 06:11AM
May-04-23 08:25AM
07:17AM
07:00AM
Apr-27-23 07:00AM
Apr-18-23 04:01PM
Mar-29-23 10:13AM
09:35AM
Mar-06-23 05:51AM
Mar-03-23 06:57PM
Mar-02-23 10:10PM
(Thomson Reuters StreetEvents) +6.29%
07:00AM
Feb-28-23 04:05PM
Feb-23-23 07:00AM
Feb-17-23 09:04AM
Feb-13-23 05:55PM
Feb-07-23 01:51PM
Feb-02-23 02:19PM
Jan-19-23 10:49AM
Jan-05-23 07:00AM
Dec-27-22 02:53PM
(American City Business Journals) -6.52%
Dec-12-22 01:41PM
(American City Business Journals)
Dec-08-22 05:00PM
Nov-29-22 12:00PM
Nov-10-22 04:30PM
09:00AM
Nov-07-22 06:06AM
Nov-04-22 12:27PM
(American City Business Journals)
07:46AM
Nov-03-22 08:15AM
07:00AM
Nov-01-22 10:01AM
Oct-27-22 04:30PM
10:02AM
Oct-26-22 11:52AM
Sep-27-22 09:59PM
(American City Business Journals)
02:52PM
(American City Business Journals)
10:13AM
Sep-26-22 04:05PM
Sep-10-22 09:16AM
Sep-06-22 07:00AM
Sep-01-22 08:48AM
Aug-30-22 02:17PM
(American City Business Journals)
Aug-29-22 10:45AM
Aug-17-22 09:29AM
Aug-09-22 04:00AM
Aug-08-22 04:01PM
07:00AM
Aug-02-22 07:00AM
Aug-01-22 04:01PM
Jul-25-22 04:30PM
09:42AM
Jul-16-22 09:45AM
Jun-24-22 03:08PM
(American City Business Journals) +13.19%
10:37AM
10:06AM
Jun-23-22 09:15AM
Jun-22-22 07:00AM
Jun-16-22 09:10AM
Jun-09-22 06:28AM
Jun-01-22 04:30PM
May-24-22 08:04AM
(American City Business Journals) -22.98%
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Jakeman David VP OF FINANCE AND ACCOUNTING Feb 14 '24 Sale 1.04 2,660 2,777 141,232 Feb 16 08:00 PM LaSpaluto Michelle CHIEF FINANCIAL OFFICER Feb 14 '24 Sale 1.04 1,940 2,023 110,999 Feb 16 08:01 PM Andriole Michael T. PRESIDENT AND CEO Feb 14 '24 Sale 1.04 1,744 1,809 447,021 Feb 16 08:02 PM MIDDLETON FRED A Director Nov 17 '23 Buy 0.96 17,295 16,522 100,000 Nov 20 03:28 PM MIDDLETON FRED A Director Nov 10 '23 Buy 0.92 2,705 2,489 82,705 Nov 13 04:39 PM Jakeman David VP of Finance and Accounting Sep 28 '23 Sale 0.99 3,610 3,584 133,142 Sep 28 04:17 PM MIDDLETON FRED A Director Sep 25 '23 Buy 0.98 20,000 19,636 80,000 Sep 26 03:58 PM Andriole Michael T. Chief Business Officer and CFO May 18 '23 Buy 1.14 51,700 59,150 357,015 May 19 11:41 AM Sherman Michael A. Chief Executive Officer May 12 '23 Buy 1.12 87,000 97,652 87,000 May 16 04:05 PM DEMSKI MARTHA J Director May 10 '23 Buy 1.11 18,000 19,980 72,055 May 11 12:26 PM Meyer Robert J. Director May 08 '23 Buy 1.14 8,750 9,975 35,150 May 10 12:51 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite